Skip to main content

Table 1 Patient clinicopathological characteristics in probiotics and placebo groups

From: A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer

ParametersProbiotic (n = 27)Placebo (n = 25)
Age in years (mean ± SD) 67.33 ± 9.4466.5 ± 8.57
Gender (n, %)Male19 (70.4)15 (60.0)
Female8 (29.6)10 (40.4)
Smoking status (n, %)Smoker8 (29.6)4 (16.0)
Ex- smoker4 (24.8)10 (56.0)
Non smoker15 (55.6)11 (44.0)
Comorbidities (n, %)Hypertension2 (7.4)2 (8.0)
Hypertension & Dyslipidaemia9 (33.3)9 (36.0)
Diabetes Mellitus(DM), Hypertension & Dyslipidaemia2 (7.4)2 (11.1)
Chronic Kidney Disease, Hypertension, DM2 (7.4)
Chronic Heart Disease, Hypertension, Dyslipidaemia1 (4.0)
Stage (n %)I1 (.37)1 (4.0)
II8 (29.6)5 (20.0)
III18 (66.7)19 (76.0)
IV
DifferentiationWell differentiated9 (33.3)5 (20.0)
Moderately differentiated18 (66.7)20 (80.0)
Poorly differentiated  
LocationRight1 (3.7)1 (4.0)
Left26 (96.3)24 (96.0)
Infection during product consumption (n, %) 
Received adjuvant therapy (n, %) 8 (29.6)6 (24.0)
Chemotherapy induced diarrhoea (n, %)
[CTCAE V 3.0]
 6 (22.2)5 (20.0)